Last reviewed · How we verify

CKD-828 — Competitive Intelligence Brief

CKD-828 (CKD-828) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Dual VEGFR2/FGFR1 tyrosine kinase inhibitor. Area: Oncology.

phase 3 Dual VEGFR2/FGFR1 tyrosine kinase inhibitor VEGFR2, FGFR1 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

CKD-828 (CKD-828) — Chong Kun Dang Pharmaceutical. CKD-828 is a dual VEGFR2/FGFR1 tyrosine kinase inhibitor that blocks angiogenesis and fibroblast growth factor signaling to inhibit tumor growth.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
CKD-828 TARGET CKD-828 Chong Kun Dang Pharmaceutical phase 3 Dual VEGFR2/FGFR1 tyrosine kinase inhibitor VEGFR2, FGFR1
Anlotinib(blank) Anlotinib(blank) Chia Tai Tianqing Pharmaceutical Group Co., Ltd. phase 3 Multi-targeted tyrosine kinase inhibitor VEGFR2, FGFR1, PDGFR-β, c-Kit, Ret

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Dual VEGFR2/FGFR1 tyrosine kinase inhibitor class)

  1. Chong Kun Dang Pharmaceutical · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CKD-828 — Competitive Intelligence Brief. https://druglandscape.com/ci/ckd-828. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: